Image via CrunchBaseThe FDA has ordered drug maker GlaxoSmithKline to stop enrolling new patients in a clinical trial of its d diabetes drug, Avandia.
The clinical trial, called TIDE, was mandated by the FDA to assess safety risks of the drug, which is prescribed to treat type-2 diabetes.
The FDA said the action does not mean the drug will be removed from the market. But the agency is demanding that GlaxoSmithKline update physicians and ethics oversight boards involved in the trial regarding all new safety information about the drug.
We are investigating claims regarding Avandia.